New schizophrenia shot tested against common pill
NCT ID NCT06315283
Summary
This study tested a new long-acting injectable form of the schizophrenia medication olanzapine against the standard oral pill. It involved 153 adults with stable schizophrenia to see how the body absorbs the medicine from each form and to check the safety of the injection. The goal was to see if the new injection could be a useful alternative for managing the condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Teva Investigational Site 15737
Marlton, New Jersey, 08053, United States
-
Teva Investigational Site 15738
Hollywood, Florida, 33024, United States
-
Teva Investigational Site 15739
Los Alamitos, California, 90720, United States
-
Teva Investigational Site 15740
Torrance, California, 90504, United States
-
Teva Investigational Site 15741
Atlanta, Georgia, 30331, United States
-
Teva Investigational Site 15742
Decatur, Georgia, 30030, United States
-
Teva Investigational Site 31326
Zamora, 49021, Spain
-
Teva Investigational Site 34310
Surrey, KT22 7AD, United Kingdom
-
Teva Investigational Site 60053
Zagreb, 10090, Croatia
Conditions
Explore the condition pages connected to this study.